Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

ABSTRACT:

Background

Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate.

Objective

To evaluate the effect of AAT on IPF progression in pirfenidone-treated patients.

Methods

This post hoc analysis included patients with IPF who received pirfenidone in 3 trials (CAPACITY [PIPF-004/PIPF-006] and ASCEND [PIPF-016]). Pulmonary function, exercise tolerance, survival, hospitalizations, and adverse events (AEs) over 52 weeks were analyzed by baseline AAT use. Disease progression was defined as a decrease in forced vital capacity (FVC) of ≥10%, a decrease in 6-min walking distance of ≥50 m, or death over 1 year.

Results

Of 623 patients, 44% received AAT. No si

SUBMITTER: Kreuter M 

PROVIDER: S-EPMC5452370 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature